We are live on ! Find out more

Catalyst Pharmaceutical

CPRX

25 hedge funds and large institutions have $24.4M invested in Catalyst Pharmaceutical in 2013 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New

Increased

Maintained

Reduced

Closed

387% more capital invested

Capital invested by funds: $5.01M → $24.4M (+$19.4M)

300% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 3

56% more funds holding

Funds holding: 16 → 25 (+9)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders

Holders Change

Holders Change %

+56.25%

% of All Funds

0.81%

Holding in Top 10

–

Holding in Top 10 Change

–

Holding in Top 10 Change %

–

% of All Funds

–

New

Increased

Reduced

Closed

Calls

–

Puts

–

Net Calls

–

Net Calls Change

–

Top Buyers

1	O OrbiMed New York	+$3.19M
2	Vanguard Group Malvern, Pennsylvania	+$1.07M
3	EI EAM Investors Solana Beach, California	+$752K
4	Renaissance Technologies New York	+$233K
5	Bank of New York Mellon New York	+$171K

Top Sellers

1	Federated Hermes Pittsburgh, Pennsylvania	-$1.26M
2	SC Sophrosyne Capital New York	-$455K
3	U UBS Zurich, Switzerland	-$16K
4	Citadel Advisors Miami, Florida	-$15K
5	CS Credit Suisse Zurich, Switzerland	-$12K

#	Name	Holding	Trade Value	Shares Change	Change in Stake
1	1 Federated Hermes Pittsburgh, Pennsylvania	$10M	-$1.26M	-749,207	-19%
2	O 2 OrbiMed New York	$5.78M	+$3.19M	+1,895,000	New
3	3 Vanguard Group Malvern, Pennsylvania	$3.64M	+$1.07M	+638,733	+115%
4	EI 4 EAM Investors Solana Beach, California	$1.36M	+$752K	+446,957	New
5	SC 5 Sophrosyne Capital New York	$732K	-$455K	-270,240	-53%
6	6 Geode Capital Management Boston, Massachusetts	$505K	–	–	–
7	7 Renaissance Technologies New York	$422K	+$233K	+138,500	New
8	TCM 8 Tanaka Capital Management New York	$414K	–	–	–
9	9 Bank of New York Mellon New York	$309K	+$171K	+101,363	New
10	10 Northern Trust Chicago, Illinois	$171K	+$21.8K	+12,979	+30%
11	11 Jane Street New York	$147K	+$81K	+48,148	New
12	12 Deutsche Bank Frankfurt Am Main Ge, Germany	$144K	+$80K	+47,529	New
13	13 Dimensional Fund Advisors Austin, Texas	$142K	–	–	–
14	14 California Public Employees Retirement System Sacramento, California	$126K	–	–	–
15	VKH 15 Virtu KCG Holdings New York	$95K	+$52.6K	+31,287	New
16	CAN 16 Cetera Advisor Networks El Segundo, California	$85K	+$47.1K	+28,000	New
17	17 Nomura Holdings Tokyo, Japan	$69K	+$38.2K	+22,700	New
18	18 Bank of America Charlotte, North Carolina	$67K	-$20	-12	-0.1%
19	GC 19 Guggenheim Capital Chicago, Illinois	$43K	+$3.17K	+1,883	+15%
20	CA 20 CapWealth Advisors Franklin, Tennessee	$40K	–	–	–
21	21 Creative Planning Overland Park, Kansas	$25K	-$2.14K	-1,274	-13%
22	LTFS 22 Ladenburg Thalmann Financial Services Miami, Florida	$17K	+$9.25K	+5,500	New
23	23 Royal Bank of Canada Toronto, Ontario, Canada	$6K	–	–	–
24	24 Citigroup New York	$2K	+$841	+500	New
25	25 AllianceBernstein Nashville, Tennessee	$1K	+$612	+364	New

CPRX Hedge Fund Activity: Q3 2013 in Review

25 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2013, worth a combined $24.4M — up 387% from $5.01M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new CPRX positions and 3 closed out — a net gain of 9 holders — while 3 added to existing stakes and 4 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $3.19M. The largest seller was Federated Hermes, cutting an estimated $1.26M.

25 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2013, up from 16 in Q2 2013.
Funds reported $24.4M of Catalyst Pharmaceutical stock for Q3 2013, up 387% quarter-over-quarter.
12 funds opened new Catalyst Pharmaceutical positions in Q3 2013 and 3 closed out, a net change of +9 holders.
The largest Catalyst Pharmaceutical buyer in Q3 2013 was OrbiMed, an estimated $3.19M added.
The largest Catalyst Pharmaceutical seller in Q3 2013 was Federated Hermes, an estimated $1.26M sold.

Based on aggregated 13F filings for Q3 2013.

Catalyst Pharmaceutical CPRX